Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 117-127

  Park, Hyun Joo ^a   Kim, Su Ryun ^a   Kim, Mi Kyoung ^a   Choi, Kyu Sil ^b   Jang, Hye Ock ^a   Yun, Il ^a   Bae, Soo Kyung ^a   Bae, Moon Kyoung ^a  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Breast cancer cells; Neuromedin B receptor antagonist; Tumor growth; Vascular endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; NEUROMEDIN B; PD 168368; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; FEMALE; HUMANS; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, BOMBESIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA;

EID: 80053304908     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.014     Document Type: Article

References (43)

1. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends. Endocrinol. Metab. 2002, 13:128-134.
2. Heasley L.E. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001, 20:1563-1569.
3. Cornelio D.B., Roesler R., Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann. Oncol. 2007, 18:1457-1466.
4. Seckl M.J., Higgins T., Widmer F., Rozengurt E. [D-Arg1, D-Trp5, 7, 9, Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res. 1997, 57:51-54.
5. Ohki-Hamazaki H., Iwabuchi M., Maekawa F. Development and function of bombesin-like peptides and their receptors. Int. J. Dev. Biol. 2005, 49:293-300.
6. Weber H.C. Regulation and signaling of human bombesin receptors and their biological effects. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16:66-71.
7. Majumdar I.D., Weber H.C. Biology of mammalian bombesin-like peptides and their receptors. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:68-74.
8. Gonzalez N., Moody T.W., Igarashi H., Ito T., Jensen R.T. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15:58-64.
9. Qu X., Xiao D., Weber H.C. Biologic relevance of mammalian bombesin-like peptides and their receptors in human malignancies. Curr. Opin. Endocrinol. Diabetes 2003, 10:60-71.
10. Jensen J.A., Carroll R.E., Benya R.V. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001, 22:689-699.
11. Taglia L., Matusiak D., Matkowskyj K.A., Benya R.V. Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G182-190.
12. Patel O., Shulkes A., Baldwin G.S. Gastrin-releasing peptide and cancer. Biochim. Biophys. Acta 2006, 1766:23-41.
13. Preston S.R., Miller G.V., Primrose J.N. Bombesin-like peptides and cancer. Crit. Rev. Oncol. Hematol. 1996, 23:225-238.
14. Martinez A., Zudaire E., Julian M., Moody T.W., Cuttitta F. Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene 2005, 24:4106-4113.
15. Matusiak D., Glover S., Nathaniel R., Matkowskyj K., Yang J., Benya R.V. Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G718-728.
16. Moody T.W., Fagarasan M., Zia F. Neuromedin B stimulates arachidonic acid release, c-fos gene expression, and the growth of C6 glioma cells. Peptides 1995, 16:1133-1140.
17. Cardona C., Rabbitts P.H., Spindel E.R., Ghatei M.A., Bleehen N.M., Bloom S.R., Reeve J.G. Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res. 1991, 51:5205-5211.
18. Park H.J., Kim S.R., Bae S.K., et al. Neuromedin B induces angiogenesis via activation of ERK and akt in endothelial cells. Exp. Cell Res. 2009, 315:3359-3369.
19. Hohla F., Schally A.V. Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer. Cell Cycle. 2010, 9:1738-1741.
20. Zhou J., Chen J., Mokotoff M., Ball E.D. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 2004, 15:921-927.
21. Hohla F., Schally A.V., Kanashiro C.A., Buchholz S., Baker B., Kannadka C., Moder A., Aigner E., Datz C., Halmos G. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-ras, COX-2, and pAkt. Proc. Natl. Acad. Sci. USA 2007, 104:18671-18676.
22. Qiao J., Kang J., Ishola T.A., Rychahou P.G., Evers B.M., Chung D.H. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc. Natl. Acad. Sci. USA 2008, 105:12891-12896.
23. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 1973, 52:2745-2756.
24. Gonzalez N., Mantey S.A., Pradhan T.K., Sancho V., Moody T.W., Coy D.H., Jensen R.T. Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides 2009, 30:1473-1486.
25. Giacchetti S., Gauville C., de Cremoux P., Bertin L., Berthon P., Abita J.P., Cuttitta F., Calvo F. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int. J. Cancer 1990, 46:293-298.
26. Yano T., Pinski J., Groot K., Schally A.V. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 1992, 52:4545-4547.
27. Aprikian A.G., Han K., Chevalier S., Bazinet M., Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J. Mol. Endocrinol. 1996, 16:297-306.
28. Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev. 2008, 60:1-42.
29. Erspamer V. Discovery, isolation, and characterization of bombesin-like peptides. Ann. NY Acad. Sci. 1988, 547:3-9.
30. Minamino N., Kangawa K., Matsuo H. Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun. 1983, 114:541-548.
31. Chao C., Ives K., Hellmich H.L., Townsend C.M., Hellmich M.R. Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression. J. Surg. Res. 2009, 156:26-31.
32. Gugger M., Reubi J.C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 1999, 155:2067-2076.
33. Miyazaki M., Lamharzi N., Schally A.V., Halmos G., Szepeshazi K., Groot K., Cai R.Z. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Eur. J. Cancer 1998, 34:710-717.
34. Bajo A.M., Schally A.V., Krupa M., Hebert F., Groot K., Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc. Natl. Acad. Sci. USA 2002, 99:3836-3841.
35. Moody T.W., Jensen R.T., Garcia L., Leyton J. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur. J. Pharmacol. 2000, 409:133-142.
36. Moody T.W., Berna M.J., Mantey S., Sancho V., Ridnour L., Wink D.A., Chan D., Giaccone G., Jensen R.T. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur. J. Pharmacol. 2010, 637:38-45.
37. Charlesworth A., Rozengurt E. Bombesin and neuromedin B stimulate the activation of p42(mapk) and p74(raf-1) via a protein kinase C-independent pathway in rat-1 cells. Oncogene 1997, 14:2323-2329.
38. Avraham R., Yarden Y. Feedback regulation of EGFR signalling: Decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12:104-117.
39. Fischer O.M., Hart S., Gschwind A., Ullrich A. EGFR signal transactivation in cancer cells. Biochem. Soc. Trans. 2003, 31:1203-1208.
40. Lo H.W., Hsu S.C., Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 2006, 95:211-218.
41. Motoshima H., Goldstein B.J., Igata M., Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 2006, 574:63-71.
42. Rattan R., Giri S., Singh A.K., Singh I. 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 2005, 280:39582-39593.
43. Jin Q., Feng L., Behrens C., Bekele B.N., Wistuba I.I., Hong W.K., Lee H.Y. Implication of AMP-activated protein kinase and akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res. 2007, 67:11630-11639.